BASEL, SWITZERLAND — Lonza has expanded its renowned human stem cell offering to supply CD34+ human cord blood hematopoietic stem cells (CB-CD34+ HSC) in large batch sizes, addressing a critical and growing market need. Lots in a range of sizes are also now available with high resolution HLA type information, eliminating the need for tedious HLA screening after lot purchase. CB-CD34+ HSCs are the preferred cellular choice for creating humanized mouse models, which are essential for preclinical safety testing of a range of immunotherapies. The new offering allows mouse model developers and researchers to increase cohort sizes to boost model building capacity, simplify the creation of HLA-compatible models, and unlock unprecedented time and cost savings.
Humanized mice are a powerful tool to explore how novel cancer biotherapies interact with a human-specific immune system comprising different and interacting cell types. In the market as a whole, there is a lack of large batch sizes of these cells, which limits the number of humanized mice that can be generated per batch of cells. Moreover, to maximize live predictability and accuracy of results, it is advantageous that the mouse models are carefully HLA matched to the grafted tumor tissue. Without ready-to-use cells available, companies are faced with lengthy internal HLA screening that can add weeks to lead times, with no guarantee that an unscreened batch will contain the desired HLA type.
Today, building on its longstanding expertise and significant investment in primary cell isolation, Lonza is able to offer a reliable and consistent supply of large batches of CB-CD34+ HSCs, as well as batches of ready-to-use cells of various sizes. As a result, customers can create larger mouse model cohorts of the exact HLA type they need, expanding testing throughput capabilities and unlocking predictive results faster and at significantly lower cost. Lonza’s breadth of inventory will also allow researchers to source all of their CB-CD34+ HSCs from a single source, ensuring consistency and reliable quality in their processes.
Aurita Menezes, Global Product Manager, Lonza, commented: “Isolating high purity CD34+ stem cells from cord blood is incredibly complex, leaving most suppliers unable to provide batch size and continuous supply. required, even without HLA typing. Lonza’s technological know-how in this area means that it leads the market with this new offering. With this, we are uniquely positioned to accelerate pathways to success for customers, further strengthening our ability to help deliver safe and affordable biotherapies to patients faster.
Lonza large cell lots are guaranteed to be >90% pure, contain ≥2 million viable cells in the lot and come with a Certificate of Analysis. HLA-Typed CB-CD34+ HSC lots are screened using reference next-generation sequencing, providing higher-resolution HLA information that minimizes the risk of common incompatibilities with standard low-level serological typing methods. resolution. Cell customers will also receive Lonza’s renowned global technical support, enabling them to quickly overcome obstacles and achieve optimal results in the creation of their mouse model.